194 related articles for article (PubMed ID: 15072437)
1. Peroxisome proliferator-activated receptors target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
Pirard B
J Comput Aided Mol Des; 2003 Nov; 17(11):785-96. PubMed ID: 15072437
[TBL] [Abstract][Full Text] [Related]
2. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures.
Oyama T; Toyota K; Waku T; Hirakawa Y; Nagasawa N; Kasuga JI; Hashimoto Y; Miyachi H; Morikawa K
Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):786-95. PubMed ID: 19622862
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators.
Zoete V; Grosdidier A; Michielin O
Biochim Biophys Acta; 2007 Aug; 1771(8):915-25. PubMed ID: 17317294
[TBL] [Abstract][Full Text] [Related]
4. Structural Biology-Based Exploration of Subtype-Selective Agonists for Peroxisome Proliferator-Activated Receptors.
Miyachi H
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502131
[TBL] [Abstract][Full Text] [Related]
5. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors.
Xu HE; Lambert MH; Montana VG; Plunket KD; Moore LB; Collins JL; Oplinger JA; Kliewer SA; Gampe RT; McKee DD; Moore JT; Willson TM
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13919-24. PubMed ID: 11698662
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.
Kuwabara N; Oyama T; Tomioka D; Ohashi M; Yanagisawa J; Shimizu T; Miyachi H
J Med Chem; 2012 Jan; 55(2):893-902. PubMed ID: 22185225
[TBL] [Abstract][Full Text] [Related]
7. Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family.
Cronet P; Petersen JF; Folmer R; Blomberg N; Sjöblom K; Karlsson U; Lindstedt EL; Bamberg K
Structure; 2001 Aug; 9(8):699-706. PubMed ID: 11587644
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol and its metabolites bind to PPARs.
Calleri E; Pochetti G; Dossou KSS; Laghezza A; Montanari R; Capelli D; Prada E; Loiodice F; Massolini G; Bernier M; Moaddel R
Chembiochem; 2014 May; 15(8):1154-1160. PubMed ID: 24796862
[TBL] [Abstract][Full Text] [Related]
9. An update about the crucial role of stereochemistry on the effects of Peroxisome Proliferator-Activated Receptor ligands.
Laghezza A; Piemontese L; Tortorella P; Loiodice F
Eur J Med Chem; 2019 Aug; 176():326-342. PubMed ID: 31112893
[TBL] [Abstract][Full Text] [Related]
10. Blocking the peroxisome proliferator-activated receptor (PPAR): an overview.
Ammazzalorso A; De Filippis B; Giampietro L; Amoroso R
ChemMedChem; 2013 Oct; 8(10):1609-16. PubMed ID: 23939910
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.
Motoshima K; Ishikawa M; Hashimoto Y; Sugita K
Bioorg Med Chem; 2011 May; 19(10):3156-72. PubMed ID: 21514830
[TBL] [Abstract][Full Text] [Related]
12. Molecular determinants for nuclear receptors selectivity: chemometric analysis, dockings and site-directed mutagenesis of dual peroxisome proliferator-activated receptors α/γ agonists.
Carrieri A; Giudici M; Parente M; De Rosas M; Piemontese L; Fracchiolla G; Laghezza A; Tortorella P; Carbonara G; Lavecchia A; Gilardi F; Crestani M; Loiodice F
Eur J Med Chem; 2013 May; 63():321-32. PubMed ID: 23502212
[TBL] [Abstract][Full Text] [Related]
13. [The structures and functions of peroxisome proliferator-activated receptors (PPARs)].
Takahashi N; Goto T; Kusudo T; Moriyama T; Kawada T
Nihon Rinsho; 2005 Apr; 63(4):557-64. PubMed ID: 15828220
[TBL] [Abstract][Full Text] [Related]
14. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
Mirza AZ; Althagafi II; Shamshad H
Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.
Markt P; Petersen RK; Flindt EN; Kristiansen K; Kirchmair J; Spitzer G; Distinto S; Schuster D; Wolber G; Laggner C; Langer T
J Med Chem; 2008 Oct; 51(20):6303-17. PubMed ID: 18821746
[TBL] [Abstract][Full Text] [Related]
16. The effect of regulating molecules on the structure of the PPAR-RXR complex.
Amber-Vitos O; Chaturvedi N; Nachliel E; Gutman M; Tsfadia Y
Biochim Biophys Acta; 2016 Nov; 1861(11):1852-1863. PubMed ID: 27616290
[TBL] [Abstract][Full Text] [Related]
17. Subtype specific effects of peroxisome proliferator-activated receptor ligands on corepressor affinity.
Stanley TB; Leesnitzer LM; Montana VG; Galardi CM; Lambert MH; Holt JA; Xu HE; Moore LB; Blanchard SG; Stimmel JB
Biochemistry; 2003 Aug; 42(31):9278-87. PubMed ID: 12899614
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.
Mahindroo N; Peng YH; Lin CH; Tan UK; Prakash E; Lien TW; Lu IL; Lee HJ; Hsu JT; Chen X; Liao CC; Lyu PC; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2006 Oct; 49(21):6421-4. PubMed ID: 17034149
[TBL] [Abstract][Full Text] [Related]
19. Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.
Nevin DK; Peters MB; Carta G; Fayne D; Lloyd DG
J Med Chem; 2012 Jun; 55(11):4978-89. PubMed ID: 22582973
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.
Pirard B; Matter H
J Med Chem; 2006 Jan; 49(1):51-69. PubMed ID: 16392792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
